You are here

Article Text

Article menu

Download PDFPDF

Infographic
Weaning down opioids in the inherited patients on high-dose opioids
Free
  1. Alaa Abd-Elsayed1 and
  2. Eric S Schwenk2
  1. 1Anesthesiology Department, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA
  2. 2Anesthesiology Department, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA
  1. Correspondence to Dr Alaa Abd-Elsayed, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA; alaaawny{at}hotmail.com

https://doi.org/10.1136/rapm-2020-102375

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Abstract

    Patients who receive high-dose opioid therapy for chronic non-cancer pain (CNCP) are at risk for opioid dependence, misuse, and overdose death. Transitions of care between physicians complicate the situation. This retrospective study described the opioid tapering experience of one outpatient pain practice that performed a slow wean over 12 months in patients maintained at least 120 mg of daily oral morphine equivalents for at least 6 months. The authors assessed compliance through patient history, state online prescription monitoring program, and frequent random urine toxicology screening. They reported that 57 of 91 patients who were evaluated (63%) achieved the meaningful reduction criterion at 12 months after the transition of care. The average reduction of daily oral morphine equivalents was 210 mg vs 127 mg in the groups that did and did not achieve meaningful reductions, respectively. The authors concluded that a slow taper in the ambulatory setting of patients with CNCP taking high-dose opioids can be successful in a substantial proportion of patients.

    Figure

    Ethics statements

    Patient consent for publication

    References

      1. Gomes T,
      2. Mamdani MM,
      3. Dhalla IA, et al
      . Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011;171:686–91.doi:10.1001/archinternmed.2011.117pmid:http://www.ncbi.nlm.nih.gov/pubmed/21482846
      OpenUrlCrossRefPubMedWeb of Science
      1. Chapman K,
      2. Pas M,
      3. Akuamoah L
      . Opioid tapering following the transfer of care of outpatient chronic non- cancer pain patients on high-dose opioid therapy. Reg Anesth Pain Med 46;2021:535–6.doi:10.1136/rapm-2020-102191

    Footnotes

    • Correction notice This article has been corrected since it published Online First. The second author's name has been corrected and the provenance and peer review statement has been included

    • Contributors All authors contributed to the design and writing of this work.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles